RadTran has developed a new approach for the generation of Ra224 and Ac225. These isotopes have been identified as the most desirable for TAT applications for both direct use and as prerequisites for two other leading medically-attractive isotopes, Pb212 and Bi213. IsoCap-AA, our patent protected technology, enables the efficient extraction of target isotopes from naturally occurring stockpiles of Thorium 232 (Th232), a natural waste byproduct of mining, at a dramatically lower cost. The stable supply of material produced using our technology will give the pharmaceutical companies the means and confidence for the development of new drugs. Furthermore, it will also provide a scalable supply once the drugs receive commercial approval.